Edwards Lifesciences overview and recent performance snapshot

Edwards Lifesciences (EW) trades around $86.00, with the stock down about 1.9% over the past day and slightly lower over the past week, while showing modest gains over the past month and past 3 months.

While Edwards Lifesciences’ share price return over the past month and past 3 months has edged higher from recent weakness, the 1-year total shareholder return of 10.47% contrasts with a modest 3-year total shareholder return of 3.02% and a 5-year total shareholder return that is 11.41% lower. This suggests that momentum has been improving in the short term, but remains mixed over longer periods.

If you are comparing Edwards Lifesciences with other healthcare-related opportunities, this could be a useful moment to broaden your watchlist using a screener focused on 39 healthcare AI stocks

With Edwards Lifesciences trading around $86.00 and showing mixed long term returns alongside recent revenue and net income growth, is the stock quietly undervalued, or are markets already factoring in its future potential?

Most Popular Narrative: 11.3% Undervalued

Edwards Lifesciences’ most followed narrative pegs fair value at $96.92, a premium to the recent $86.00 close, framing the stock as modestly undervalued on that view.

The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Want to understand why this narrative supports a higher fair value than today’s price? It leans heavily on sustained revenue growth, rising margins and a premium earnings multiple that assumes investors keep paying up for that profile.

The valuation work behind this narrative uses a discount rate of 7.56%, projected top line expansion and a higher future profit margin to arrive at $96.92, then compares that against current earnings power and share count expectations to judge whether today’s price builds in enough of that growth story.

Result: Fair Value of $96.92 (UNDERVALUED)

However, this depends on tariffs and the JenaValve acquisition not weighing more heavily on margins or EPS than analysts currently build into their models.

Another angle on valuation

While the fair value model suggests Edwards Lifesciences is trading about 3.9% below estimated intrinsic value, its P/E of 46x is far higher than the estimated fair ratio of 28.9x and above both the US Medical Equipment industry at 24.2x and peers at 24.9x. This points to clear valuation risk if growth expectations slip.

For a closer look at how this pricing gap compares with earnings power, you can review the detailed valuation breakdown, including the fair ratio and peer comparisons, in our full assessment of Edwards Lifesciences, then decide which signal you think carries more weight for your own process. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, this is a moment to look at the numbers yourself, weigh both sides, and see the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better, so use screeners to quickly surface ideas that match your style.

• Spot potential value opportunities early by scanning companies filtered as 47 high quality undervalued stocks and see which ones deserve a closer look.
• Prioritize resilience by reviewing stocks in the 63 resilient stocks with low risk scores that score well on stability and downside protection.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems and seeing which underfollowed stocks might complement your current holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.